{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:46:47Z","timestamp":1784958407436,"version":"3.55.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Plasma Protein Therapeutic Association"},{"name":"Plasma Protein Therapeutic Association"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Common variable immunodeficiency disorders (CVID), the most common form of primary antibody deficiency, are rare conditions associated with considerable morbidity and mortality. The clinical benefit of immunoglobulin replacement therapy (IgGRT) is substantial: timely treatment with appropriate doses significantly reduces mortality and the incidence of CVID-complications such as major infections and bronchiectasis. Unfortunately, CVID-patients still face a median diagnostic delay of 4 years. Their disease burden, expressed in annual loss of disability-adjusted life years, is 3-fold higher than in the general population. Hurdles to treatment access and reimbursement by healthcare payers may exist because the value of IgGRT is poorly documented. This paper aims to demonstrate cost-effectiveness and cost-utility (on life expectancy and quality) of IgGRT in CVID.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods and findings<\/jats:title><jats:p>With input from a literature search, we built a health-economic model for cost-effectiveness and cost-utility assessment of IgGRT in CVID. We compared a mean literature-based dose (\u2265450mg\/kg\/4wks) to a zero-or-low dose (0 to \u2264100 mg\/kg\/4wks) in a simulated cohort of adult patients from time of diagnosis until death; we also estimated the economic impact of diagnostic delay in this simulated cohort.<\/jats:p><jats:p>Compared to no or minimal treatment, IgGRT showed an incremental benefit of 17 life-years (LYs) and 11 quality-adjusted life-years (QALYs), resulting in an incremental cost-effectiveness ratio (ICER) of \u20ac29,296\/LY and \u20ac46,717\/QALY. These results were robust in a sensitivity analysis. Reducing diagnostic delay by 4 years provided an incremental benefit of six LYs and four QALYs compared to simulated patients with delayed IgGRT initiation, resulting in an ICER of \u20ac30,374\/LY and \u20ac47,495\/QALY.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Conclusions<\/jats:title><jats:p>The health-economic model suggests that early initiation of IgGRT compared to no or delayed IgGRT is highly cost-effective. CVID-patients\u2019 access to IgGRT should be facilitated, not only because of proven clinical efficacy, but also due to the now demonstrated cost-effectiveness.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0247941","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T19:01:08Z","timestamp":1614884468000},"page":"e0247941","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Disorders (CVID): A health-economic assessment"],"prefix":"10.1371","volume":"16","author":[{"given":"Philippe","family":"van Wilder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Odnoletkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Mouline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4311-3550","authenticated-orcid":true,"given":"Esther","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"pone.0247941.ref001","unstructured":"European Medicines Agency. Orphan drugs and Rare Diseases at a Glance. Accessed June 8th 2020 via: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/orphan-designation-overview."},{"issue":"2015","key":"pone.0247941.ref002","first-page":"906","article-title":"Rare Disease Terminology and Definitions\u2014A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group","volume":"18","author":"T Richter","journal-title":"Value in health"},{"issue":"201","key":"pone.0247941.ref003","first-page":"2018","article-title":"Orphanet Journal of Rare Diseases","volume":"13","author":"Odnoletkova","journal-title":"The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data"},{"issue":"6","key":"pone.0247941.ref004","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jaci.2011.02.039","article-title":"Genome-wide association identifies diverse causes of common variable immunodeficiency","volume":"127","author":"JS Orange","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"pone.0247941.ref005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common variable immunodeficiency disorders: division into distinct clinical phenotypes","volume":"112","author":"H Chapel","year":"2008","journal-title":"Blood"},{"key":"pone.0247941.ref006","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12728","article-title":"Common variable immune deficiency: Dissection of the variable","volume":"287","author":"C Cunningham\u2010Rundles","year":"2019","journal-title":"Immunological Reviews"},{"issue":"1","key":"pone.0247941.ref007","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10875-017-0456-9","article-title":"Autoimmune Cytopenias and Associated Conditions in CVID: a Report From the USIDNET Registry","volume":"38","author":"EJ Feuille","year":"2018","journal-title":"J Clin Immunol"},{"issue":"5","key":"pone.0247941.ref008","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.anai.2019.07.014","article-title":"Autoimmunity in common variable immunodeficiency","volume":"123","author":"S Agarwal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"pone.0247941.ref009","doi-asserted-by":"crossref","first-page":"648","DOI":"10.14309\/ajg.0000000000000140","article-title":"A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency","volume":"114","author":"S Pikkarainen","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"pone.0247941.ref010","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/1744666X.2019.1658523","article-title":"Malignancy in common variable immunodeficiency: a systematic review and meta-analysis","volume":"15","author":"F Kiaee","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"pone.0247941.ref011","doi-asserted-by":"crossref","first-page":"e12663","DOI":"10.1111\/sji.12663","article-title":"Rheumatologic complications in a cohort of 227 patients with common variable immunodeficiency","volume":"87","author":"G Azizi","year":"2018","journal-title":"Scand J Immunol"},{"key":"pone.0247941.ref012","unstructured":"Orphanet. The portal for rare diseases and orphan drugs. Common variable immunodeficiency. Accessed June 8th, 2020 via https:\/\/www.orpha.net\/consor4.01\/www\/cgi-bin\/OC_Exp.php?lng = EN&Expert = 1572."},{"issue":"1","key":"pone.0247941.ref013","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies","volume":"137","author":"JS Orange","year":"2010","journal-title":"Clin Immunol"},{"issue":"1","key":"pone.0247941.ref014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12026-011-8241-y","article-title":"Global study of primary immunodeficiency diseases (PI)\u2014diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation","volume":"51","author":"V Modell","year":"2011","journal-title":"Immunol Res"},{"key":"pone.0247941.ref015","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40273-015-0309-4","article-title":"Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice","volume":"33","author":"J O\u2019Mahony","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"pone.0247941.ref016","unstructured":"National Institute for Health and Care Excellence. The principles that guide the development of NICE guidance and standards. Accessed June 9th, 2020 via https:\/\/www.nice.org.uk\/about\/who-we-are\/our-principles."},{"key":"pone.0247941.ref017","first-page":"50","article-title":"Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)Orphanet journal of Rare Diseases","volume":"12","author":"Annemans","year":"2017"},{"issue":"1","key":"pone.0247941.ref018","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","article-title":"International Consensus Document (ICON): Common Variable Immunodeficiency Disorders","volume":"4","author":"FA Bonilla","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"pone.0247941.ref019","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"SPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20141","volume":"15","author":"JJ Caro","year":"2012","journal-title":"Value Health"},{"issue":"7587","key":"pone.0247941.ref020","first-page":"163","article-title":"Summary report of a Medical Research Council working-party","volume":"1","author":"Hypogammaglobulinaemia in the United Kingdom","year":"1969","journal-title":"Lancet"},{"issue":"1","key":"pone.0247941.ref021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/clim.1999.4725","article-title":"Common variable immunodeficiency: clinical and immunological features of 248 patients","volume":"92","author":"C Cunningham-Rundles","year":"1999","journal-title":"Clinical Immunology"},{"key":"pone.0247941.ref022","unstructured":"National Institute for Public Health and the Environment. Ministry of Health, Welfare and Sport. Quantification and valuation of the human health impacts of chemicals based on quality and disability-adjusted life-years. Final Report. ECHA Framework Contract\u2013QALYs and DALYs SR19, 2015."},{"key":"pone.0247941.ref023","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies","volume":"137","author":"JS Orange","year":"2010","journal-title":"Clinical Immunology"},{"key":"pone.0247941.ref024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"A Briggs","year":"2006"},{"key":"pone.0247941.ref025","unstructured":"WHO guide for standardization of economic evaluations of immunization programmes. October 2019. WHO\/IVB\/19.10."},{"key":"pone.0247941.ref026","article-title":"Belgian Health Care Knowledge Centre","author":"I Cleemput","year":"2012","journal-title":"Belgian guidelines for economic evaluations and budget impact analyses: second edition Report 183C"},{"key":"pone.0247941.ref027","unstructured":"European network for health technology assessment. Methods for health economic evaluations\u2014A guideline based on current practices in Europe 2015. https:\/\/www.eunethta.eu\/wp-content\/uploads\/2018\/03\/Methods_for_health_economic_evaluations.pdf."},{"issue":"2","key":"pone.0247941.ref028","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"E Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"key":"pone.0247941.ref029","unstructured":"EuropaBio. Position Papers. Health Technology Assessment. Accessd June 9th 2020 via https:\/\/www.europabio.org\/healthcare-biotech\/publications\/biotech-products-and-hta."},{"issue":"2019","key":"pone.0247941.ref030","first-page":"105734","article-title":"A review of the cost-effectiveness of adult influenza vaccination and other preventive services.","volume":"126","author":"Dabestani","journal-title":"Preventive Medicine"},{"key":"pone.0247941.ref031","article-title":"Access to orphan medicinal products despite a low level of evidence","author":"AG Dupont","year":"2014","journal-title":"Br.J Clin Pharmacol"},{"key":"pone.0247941.ref032","unstructured":"KCE Report 327, 2020. https:\/\/kce.fgov.be\/sites\/default\/files\/atoms\/files\/KCE_327_Polyvalent_Immunoglobulines_Report.pdf."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T10:53:06Z","timestamp":1724583186000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247941"}},"subtitle":[],"editor":[{"given":"Kevin","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0247941","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]}}}